U.S. Markets open in 17 mins
  • S&P Futures

    3,648.75
    -11.75 (-0.32%)
     
  • Dow Futures

    29,663.00
    -141.00 (-0.47%)
     
  • Nasdaq Futures

    12,399.25
    -53.00 (-0.43%)
     
  • Russell 2000 Futures

    1,825.50
    -10.00 (-0.54%)
     
  • Crude Oil

    44.43
    -0.12 (-0.27%)
     
  • Gold

    1,822.60
    +3.70 (+0.20%)
     
  • Silver

    23.88
    -0.21 (-0.87%)
     
  • EUR/USD

    1.2071
    -0.0007 (-0.0604%)
     
  • 10-Yr Bond

    0.9410
    +0.0070 (+0.75%)
     
  • Vix

    21.13
    +0.56 (+2.72%)
     
  • GBP/USD

    1.3304
    -0.0119 (-0.8874%)
     
  • USD/JPY

    104.5890
    +0.2730 (+0.2617%)
     
  • BTC-USD

    19,106.94
    +113.03 (+0.60%)
     
  • CMC Crypto 200

    374.62
    -5.24 (-1.38%)
     
  • FTSE 100

    6,412.41
    +27.68 (+0.43%)
     
  • Nikkei 225

    26,800.98
    +13.44 (+0.05%)
     

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

BURNABY, British Columbia, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will participate in the following investor conferences and present a company update when noted:

  • Guggenheim Healthcare Talks | Idea Forum | Neuro/Immunology Day on Monday, November 18, 2019;

  • Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:35 pm ET; and

  • Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019 at 4:00 pm GMT.

The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the on the “Investors” section of Xenon's website at www.xenon-pharma.com. All webcasts will be posted for replay following the event for 30 days.

About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com